About Sodium/bile acid cotransporter 5
Sodium/bile acid cotransporter 5 (SLC10A5) is a protein
from Homo sapiens identified by UniProt accession
Q5PT55, 438 residues long.
MolForge cross-references it against 0 known binders and
17 disease associations.
Target properties
| Protein name | Sodium/bile acid cotransporter 5 |
| UniProt accession | Q5PT55 |
| Gene | SLC10A5 |
| Organism | Homo sapiens |
| Length | 438 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (17)
Diseases linked to this target (Open Targets).
- reticulocyte count · score 0.16
- platelet crit · score 0.15
- platelet count · score 0.09
- ovarian carcinoma · score 0.03
- mean platelet volume · score 0.03
- ovarian serous carcinoma · score 0.02
- age-related hearing impairment · score 0.02
- cystatin C measurement · score 0.02
- blood phosphate measurement · score 0.02
- malignant epithelial tumor of ovary · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q5PT55-F1 | alphafold | PREDICTED | 80.21 | — |
Amino-acid sequence (438 residues)
MIRKLFIVLL LLLVTIEEAR MSSLSFLNIE KTEILFFTKT EETILVSSSY ENKRPNSSHL FVKIEDPKIL QMVNVAKKIS SDATNFTINL VTDEEGETNV TIQLWDSEGR QERLIEEIKN VKVKVLKQKD SLLQAPMHID RNILMLILPL ILLNKCAFGC KIELQLFQTV WKRPLPVILG AVTQFFLMPF CGFLLSQIVA LPEAQAFGVV MTCTCPGGGG GYLFALLLDG DFTLAILMTC TSTLLALIMM PVNSYIYSRI LGLSGTFHIP VSKIVSTLLF ILVPVSIGIV IKHRIPEKAS FLERIIRPLS FILMFVGIYL TFTVGLVFLK TDNLEVILLG LLVPALGLLF GYSFAKVCTL PLPVCKTVAI ESGMLNSFLA LAVIQLSFPQ SKANLASVAP FTVAMCSGCE MLLIILVYKA KKRCIFFLQD KRKRNFLI
Explore Sodium/bile acid cotransporter 5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets